NO20090342L - Cancersykdom-modifiserende antistoffer - Google Patents
Cancersykdom-modifiserende antistofferInfo
- Publication number
- NO20090342L NO20090342L NO20090342A NO20090342A NO20090342L NO 20090342 L NO20090342 L NO 20090342L NO 20090342 A NO20090342 A NO 20090342A NO 20090342 A NO20090342 A NO 20090342A NO 20090342 L NO20090342 L NO 20090342L
- Authority
- NO
- Norway
- Prior art keywords
- cancer
- antibodies
- cancer disease
- modifying antibodies
- modifying
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 6
- 201000011510 cancer Diseases 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000001093 anti-cancer Effects 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 208000013210 hematogenous Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002285 radioactive effect Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 108700012359 toxins Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Optics & Photonics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
Abstract
SAMMENDRAG Den foreliggende oppfinnelse vedrører en fremgangsmåte for fremstilling av cancersykdom-modifiserende antistoffer fra en pasient ved anvendelse av en ny paradigme for screening. Ved segregering av anti-cancer-antistoffene ved anvendelse av cancercelle-cytotoksisitet som et sluttpunkt, muliggjør prosessen fremstilling av anti-cancer-antistoffer for terapeutiske og diagnostiske formål. Antistoffene kan anvendes til å hjelpe til ved stadiumbestemmelse og diagnose av en cancer, og kan anvendes til å behandle primære tumorer og tumormetastaser. Anti-cancer-antistoffene kan være konjugert til toksiner, enzymer, radioaktive forbindelser, og hematogene celler.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83343106P | 2006-07-26 | 2006-07-26 | |
PCT/CA2007/001318 WO2008011711A1 (en) | 2006-07-26 | 2007-07-24 | Cancerous disease modifying antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20090342L true NO20090342L (no) | 2009-04-27 |
Family
ID=38981089
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20090342A NO20090342L (no) | 2006-07-26 | 2009-01-22 | Cancersykdom-modifiserende antistoffer |
Country Status (12)
Country | Link |
---|---|
US (1) | US20080089891A1 (no) |
EP (1) | EP2044119A4 (no) |
JP (1) | JP2009545528A (no) |
KR (1) | KR20090059106A (no) |
CN (1) | CN101547936A (no) |
AU (1) | AU2007278792A1 (no) |
BR (1) | BRPI0715544A2 (no) |
CA (1) | CA2666515A1 (no) |
MX (1) | MX2009001015A (no) |
NO (1) | NO20090342L (no) |
RU (1) | RU2009104624A (no) |
WO (1) | WO2008011711A1 (no) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140135233A (ko) | 2012-03-14 | 2014-11-25 | 리제너론 파마슈티칼스 인코포레이티드 | 다중특이성 항원-결합 분자 및 그것의 용도 |
WO2017190079A1 (en) | 2016-04-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
WO2018226861A1 (en) | 2017-06-07 | 2018-12-13 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
CN112074538A (zh) | 2018-04-30 | 2020-12-11 | 瑞泽恩制药公司 | 结合her2和/或aplp2的抗体和双特异性抗原结合分子、其缀合物和用途 |
EP4210735A1 (en) | 2020-09-10 | 2023-07-19 | Vascular Biogenics Ltd. | Motile sperm domain containing protein 2 antibodies and methods of use thereof |
WO2022208320A1 (en) * | 2021-03-29 | 2022-10-06 | Vascular Biogenics Ltd. | Motile sperm domain containing protein 2, integrin beta2 and cd63 |
KR102627688B1 (ko) | 2021-11-09 | 2024-01-23 | 호서대학교 산학협력단 | 죽단화 꽃 에센셜오일을 유효성분으로 포함하는 피부 재생 및 주름 개선용 화장료 조성물 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4172124A (en) * | 1978-04-28 | 1979-10-23 | The Wistar Institute | Method of producing tumor antibodies |
US4867973A (en) * | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
US4828991A (en) * | 1984-01-31 | 1989-05-09 | Akzo N.V. | Tumor specific monoclonal antibodies |
AU613590B2 (en) * | 1986-11-19 | 1991-08-08 | Bristol-Myers Squibb Company | Hybridomas producing monoclonal antibodies to new mucin epitopes |
US4861581A (en) * | 1986-12-05 | 1989-08-29 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
US5171665A (en) * | 1989-04-17 | 1992-12-15 | Oncogen | Monoclonal antibody to novel antigen associated with human tumors |
US5296348A (en) * | 1989-05-16 | 1994-03-22 | The Wistar Institute Of Anatomy And Biology | Methods for screening monoclonal antibodies for therapeutic use |
US6020145A (en) * | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
EP0539970B1 (en) * | 1991-10-30 | 1999-05-26 | Idemitsu Kosan Company Limited | Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby |
IL105008A0 (en) * | 1992-03-13 | 1993-07-08 | Yeda Res & Dev | Double transfectants of mhc genes as cellular vaccines for immunoprevention of tumor metastasis |
US5545532A (en) * | 1993-02-05 | 1996-08-13 | Epigen, Inc. | Human carcinoma antigen (HCA), HCA antibodies, HCA immunoassays and methods of imaging |
JPH10505819A (ja) * | 1994-06-24 | 1998-06-09 | ヴラディミール ピー. トーチリン | 腫瘍の治療及び予防のための自己抗体の使用方法 |
US5783186A (en) * | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
US6783961B1 (en) * | 1999-02-26 | 2004-08-31 | Genset S.A. | Expressed sequence tags and encoded human proteins |
AU4441799A (en) * | 1998-06-15 | 2000-01-05 | Research Foundation Of The State University Of New York, The | Monoclonal antibodies that recognize antigens associated with tumor metastasis |
US6657048B2 (en) * | 1999-10-08 | 2003-12-02 | Arius Research, Inc. | Individualized anti-cancer antibodies |
US6180357B1 (en) * | 1999-10-08 | 2001-01-30 | Arius Research, Inc. | Individualized patient-specific anti-cancer antibodies |
US20040105816A1 (en) * | 1999-10-08 | 2004-06-03 | Young David S. F. | Cancerous disease modifying antibodies |
US7256271B2 (en) * | 2003-01-21 | 2007-08-14 | Arius Research Inc. | Cancerous disease modifying antibodies |
US7442776B2 (en) * | 1999-10-08 | 2008-10-28 | Young David S F | Cancerous disease modifying antibodies |
US20020102638A1 (en) * | 2000-01-31 | 2002-08-01 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
WO2001075177A2 (en) * | 2000-04-03 | 2001-10-11 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Tumor markers in ovarian cancer |
US7361343B2 (en) * | 2003-01-21 | 2008-04-22 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
US7009040B2 (en) * | 2003-01-21 | 2006-03-07 | Arius Research, Inc. | Cancerous disease modifying antibodies |
US20060210474A1 (en) * | 2000-11-29 | 2006-09-21 | Young David S | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
US7431923B2 (en) * | 2005-01-03 | 2008-10-07 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
US20030055220A1 (en) * | 2001-01-12 | 2003-03-20 | Pierre Legrain | Protein-protein interactions between Shigella flexneri polypeptides and mammalian polypeptides |
US6783969B1 (en) * | 2001-03-05 | 2004-08-31 | Nuvelo, Inc. | Cathepsin V-like polypeptides |
CA2444675A1 (en) * | 2001-04-20 | 2002-10-31 | Chandra S. Arvizu | Secreted proteins |
EP2153843B1 (en) * | 2001-09-18 | 2012-08-15 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
CA2471206A1 (en) * | 2001-12-21 | 2003-07-10 | Arius Research, Inc. | Individualized anti-cancer antibodies |
US7361342B2 (en) * | 2003-01-21 | 2008-04-22 | Arius Research Inc. | Cancerous disease modifying antibodies |
US7393531B2 (en) * | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
-
2007
- 2007-07-23 US US11/880,619 patent/US20080089891A1/en not_active Abandoned
- 2007-07-24 EP EP07784985A patent/EP2044119A4/en not_active Withdrawn
- 2007-07-24 CA CA002666515A patent/CA2666515A1/en not_active Abandoned
- 2007-07-24 BR BRPI0715544-1A2A patent/BRPI0715544A2/pt not_active Application Discontinuation
- 2007-07-24 AU AU2007278792A patent/AU2007278792A1/en not_active Abandoned
- 2007-07-24 KR KR1020097001773A patent/KR20090059106A/ko not_active Application Discontinuation
- 2007-07-24 WO PCT/CA2007/001318 patent/WO2008011711A1/en active Application Filing
- 2007-07-24 CN CNA200780030641XA patent/CN101547936A/zh active Pending
- 2007-07-24 JP JP2009521074A patent/JP2009545528A/ja active Pending
- 2007-07-24 MX MX2009001015A patent/MX2009001015A/es not_active Application Discontinuation
- 2007-07-24 RU RU2009104624/10A patent/RU2009104624A/ru unknown
-
2009
- 2009-01-22 NO NO20090342A patent/NO20090342L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20090059106A (ko) | 2009-06-10 |
JP2009545528A (ja) | 2009-12-24 |
EP2044119A1 (en) | 2009-04-08 |
BRPI0715544A2 (pt) | 2014-10-29 |
AU2007278792A1 (en) | 2008-01-31 |
CN101547936A (zh) | 2009-09-30 |
WO2008011711A1 (en) | 2008-01-31 |
MX2009001015A (es) | 2009-06-22 |
EP2044119A4 (en) | 2010-09-01 |
CA2666515A1 (en) | 2008-01-31 |
US20080089891A1 (en) | 2008-04-17 |
RU2009104624A (ru) | 2010-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1718737T3 (da) | Cancerøs sygdomsmodificerende antistoffer | |
NO20090342L (no) | Cancersykdom-modifiserende antistoffer | |
WO2007095749A8 (en) | Cytotoxicity mediation of cells evidencing surface expression of trop-2 | |
NO20066075L (no) | Antistofflegemiddelkonjugater og fremgangsmater | |
MX2009007619A (es) | Anticuerpos modificadores de una enfermedad cancerigena. | |
WO2007074193A3 (es) | Método de análisis de expresión diferencial en cáncer colorectal | |
MX2010005966A (es) | Conjugados de anticuerpo monoclonal-molecula asociada dirigidos a la proteina tirosina-cinasa 7 (ptk7). | |
EA201290138A1 (ru) | Производные пиразола как модуляторы кальциевых каналов, активируемых высвобождением кальция | |
DK1613656T3 (da) | Cancersygdomsmodificerende antistoffer | |
WO2004065422A3 (en) | Cancerous disease modifying antibodies | |
EA201070085A1 (ru) | Потенцирование химиотерапии рака | |
WO2003086456A3 (en) | Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer | |
MX2009007617A (es) | Anticuerpos modificadores de una enfermedad cancerigena. | |
MX2009007618A (es) | Anticuerpos modificadores de una enfermedad cancerigena. | |
WO2005012361A3 (en) | Antibodies raised against colon carcinomas | |
GB0718878D0 (en) | Photodynamic Theraphy and diagnosis | |
WO2008092002A3 (en) | Compositions and methods for treating and diagnosing pancreatic cancer | |
NO20091459L (no) | Cancerose sykdomsmodifiserende antistoffer | |
NO20091458L (no) | Cancerose sykdomsmodifiserende antistoffer | |
EP1929034A4 (en) | ANTIBODIES CAPABLE OF MODIFYING EVOLUTION OF CANCER DISEASE | |
MX2009009919A (es) | Anticuerpo 010207-01 modificador de la enfermedad del cancer, producido por la linea celular ar51a630.3 del hibridoma. | |
MX2009011667A (es) | Anticuerpos de modificacion de enfermedad cancerosa. | |
MX2009001292A (es) | Anticuerpos modificadores de enfermedad cancerosa. | |
NO20091460L (no) | Cancerose sykdomsmodifiserende antistoffer | |
NZ581416A (en) | Antibodies useful for therapy and diagnosis of melanoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |